Anacrotine
Anacrotine produces much more severe lung damage than most other pyrrolizidine alkaloids.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
J Pharmaceut Biomed2020, 182:113110
Comput Biol Med.2024, 178:108775.
Antioxidants (Basel).2019, 8(8):E307
Sci Rep.2019, 9(1):4342
Jeju National University Graduate School2023, 24478
Eur J Pharmacol.2023, 950:175772.
Daru.2024, 32(2):689-703.
J Biol Chem.2014, 289(3):1723-31
Korean Journal of Pharmacognosy.2020, 51(2):100-106
Front Pharmacol.2018, 9:236
Related and Featured Products
Chem Biol Interact. 1987;63(1):91-104.
Metabolism and toxicity of anacrotine, a pyrrolizidine alkaloid, in rats.[Pubmed:
3652286]
The effects of Anacrotine, a pyrrolizidine alkaloid (PA) which has the structure of senecionine with an additional 6-hydroxy group, have been investigated in weanling male rats.
METHODS AND RESULTS:
When Anacrotine was given i.p. (100 mg/kg), pyrrolic metabolites reached a peak level in the liver during the first 0.5 h, then fell rapidly to a lower level which subsequently declined more slowly. Anacrotine caused acute centrilobular necrosis and congestion of the liver when 125 mg/kg or more was given i.p., but oral doses (up to 180 mg/kg) caused relatively little liver necrosis.In contrast, Anacrotine produced much more severe lung damage than most other pyrrolizidine alkaloids. Hearts showed myocardial necrosis of the right ventricular wall. DehydroAnacrotine, the putative reactive pyrrolic metabolite of Anacrotine, given i.v. to rats, caused dose-related chronic lung and heart damage identical to that produced by Anacrotine, but after lower doses (6-27 mg/kg); larger amounts caused acute lung damage.
CONCLUSIONS:
It is suggested that the severe lung damage in animals given Anacrotine is due to dehydroAnacrotine, formed in the liver.
